Screener
Beam Therapeutics BEAM Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiGainLoss.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (107,215) | (119,286) |
| Other income (expense): | ||
| Change in fair value of derivative liabilities | 2,500 | 3,200 |
| Change in fair value of non-controlling equity investments | 16 | (2,081) |
| Change in fair value of contingent consideration liabilities | 514 | (27) |
| Interest and other income (expense), net | 9,867 | 9,864 |
| Total other income (expense) | 12,897 | 10,956 |
| Net loss | $(94,318) | $(108,330) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's net gains (losses) on investments?
- Beam Therapeutics (BEAM) reported net gains (losses) on investments of $16K in Q1 2026.
- How has Beam Therapeutics's net gains (losses) on investments changed year-over-year?
- Beam Therapeutics's net gains (losses) on investments increased by 100.8% year-over-year, from -$2.08M to $16K.
- What is the long-term trend for Beam Therapeutics's net gains (losses) on investments?
- Over 2 years (2022 to 2024), Beam Therapeutics's net gains (losses) on investments has grown at a -16.5% compound annual growth rate (CAGR), from $20.2M to -$14.09M.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about Beam Therapeutics's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude